Ticagrelor resistance: a case series and algorithm for management of non-responders
- PMID: 34215660
- DOI: 10.1136/neurintsurg-2021-017638
Ticagrelor resistance: a case series and algorithm for management of non-responders
Abstract
The placement of cervical and intracranial stents requires the administration of antiplatelet drugs to prevent thromboembolic complications. Ticagrelor has emerged as the most widely used alternative in clopidogrel non-responders owing to its potent antiplatelet effects. Because ticagrelor does not require hepatic activation, many neurointerventionalists choose to forgo laboratory testing of platelet inhibition. In rare instances, patients may not achieve adequate platelet inhibition following ticagrelor administration. In this paper we review the mechanism of action of ticagrelor and its use in cerebrovascular procedures. We present two cases of ticagrelor non-responsiveness from two high-volume cerebrovascular centers, discuss their management, and propose an algorithm for managing ticagrelor non-responsiveness.
Keywords: pharmacology; platelets; standards; stent; stroke.
© Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by BMJ.
Conflict of interest statement
Competing interests: BH is a lead investigator of the CAPTIVA RCT trial. AstraZeneca is supporting the CAPTIVA trial by providing ticagrelor (https://www.nihstrokenet.org/docs/default-source/default-document-library/hoh-captiva-9-12-18-v3ef07f0d0c2c66f0f86baff000016a715.pdf?sfvrsn=0).
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical